Better Buy: AbbVie Inc. vs. Pfizer Inc.
There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer.
But, as the statements read on mutual fund, past performance is no guarantee of future results. Which stock is the better pick for long-term investors now? Here's how AbbVie and Pfizer compare.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€26.01
0.620%
The stock is one of the favorites of our community with 31 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 57.63% compared to the current price of 26.01 € for Pfizer Inc..
